MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to p ...

Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointme ...

Core Insights - Opthea Limited has successfully completed its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept, a significant step towards a potential biologics license application (BLA) filing for the treatment of wet age-related macular degeneration (wet AMD) [1][2] - The completion of the PPQ campaign involved the production of three consecutive commercial-scale drug substance batches, validating Opthea's manufacturing process [1][2] - The company is advancing two pivotal Phase 3 trials of sozinibercept, demonstrating its capability to consistently manufacture quality drug substance at a commercial scale, which is crucial for the BLA Chemistry, Manufacturing and Controls (CMC) module [2][4] Company Overview - Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, including wet AMD and diabetic macular edema (DME) [3] - The lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials aimed at improving efficacy and vision gains compared to standard anti-VEGF-A agents [4]

MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced scientific presentations and a non-CME educational lunch symposium highlighting sozinibercept's potential to become the first therapy in 20 years to improve visual outcomes ...

MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present and participate in one-on-one investor meetings at the following two investor conferences in September 2024: H.C. Wainwright 26th Annual Global ...

Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in preparation for regulatory filing and launch of sozinibercept MELBOURNE, Australia, and PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, ...

MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024. Virtual C ...

MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, Fran ...

Dante Pieramici, MD, is a Managing Partner at California Retina Consultants and a member of the Medical Leadership Board of the Retina Consultants of America. As the Medical Director of Clinical Research at California Retina Consultants, he has served as a principal or sub-investigator in over 100 clinical trials. He has also served as an advisor to multiple pharmaceutical companies, helping design and evaluate clinical trials, and has served on several data and safety monitoring committees. Authorized for ...

| --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------| | | | | Item | Date | | Settlement of New Shares under the Retail Entitlement Offer and any shortfall under the Retail Entitlement Offer | Tuesday, 16 July 2024 | | Allotment and issue of New Shares and New Options under the Retail Entitlement Offer, and New Options issued under the Institutional Entit ...